Shan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shan Wang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Yiping Yang
Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China
8 shared publicationsYingxi Mo
Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China
7 shared publicationsYurun Huang
Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China
6 shared publications- Qingyun Zhang
Department of Urology, Guangxi Medical University Cancer Hospital, Nanning 530021, China
5 shared publications Menghan Zhou
Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China
4 shared publications- Wang Guo
State Key Laboratory of Featured Metal Materials and Life-Cycle Safety for Composite Structures, School of Mechanical Engineering, Guangxi University, Nanning 530004, China
4 shared publications
Latest Publications
- 30 June 2026
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 42 (27) , 19878-19892
Polydopamine/Cerium Oxide Nanoparticle Coating on 3D-Printed Photothermal Shape-Memory Bone Scaffolds for Synergistic Antibacterial and Antitumor Applications
Addressing complex bone defects associated with infection and tumors requires advanced surface and biointerface engineering of biomaterials. This study presents a surface functionalization strategy for constructing a multifunctional coating on a 3D-printed shape-memory polymer composite (PLA/PEG/MoS2) substrate. Utilizing a polydopamine (PD)-mediated deposition process, cerium oxide nanoparticles (CeO2 NPs) were uniformly immobilized onto the scaffold surface to create a tailored, functionally active coating. This coating markedly altered the surface physicochemical properties, reducing the water contact angle from approximately 81° to 48°, and enhanced interfacial biomineralization and the osteoblastic response of MC3T3-E1 cells. Moreover, the designed substrate-coating architecture integrated bulk photothermal responsiveness with surface-mediated nanoparticle activity, enabling a synergistic therapeutic mode at the biointerface. Under near-infrared (NIR) irradiation, the photothermal heat generated by the MoS2-incorporated scaffold triggered shape-memory recovery for adaptive defect fitting while simultaneously amplifying the antibacterial and antitumor efficacy of the PD/CeO2 coating. As a result, the multifunctional scaffold achieved antibacterial rates of 92% against E. coli and 94% against S. aureus, together with a 92% ablation rate of human osteosarcoma (HOS) cells. Overall, this work demonstrates a potential functional-coating strategy for engineering a multifunctional biointerface on 3D-printed bone scaffolds, integrating surface bioactivity, NIR-triggered shape-memory behavior, and synergistic photothermal/nanoparticle therapy. These findings provide a promising design for functional coatings and surface-engineered biomaterials in the treatment of complex bone defects.
- 30 June 2026
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 42 (27) , 19878-19892
Polydopamine/Cerium Oxide Nanoparticle Coating on 3D-Printed Photothermal Shape-Memory Bone Scaffolds for Synergistic Antibacterial and Antitumor Applications
Addressing complex bone defects associated with infection and tumors requires advanced surface and biointerface engineering of biomaterials. This study presents a surface functionalization strategy for constructing a multifunctional coating on a 3D-printed shape-memory polymer composite (PLA/PEG/MoS2) substrate. Utilizing a polydopamine (PD)-mediated deposition process, cerium oxide nanoparticles (CeO2 NPs) were uniformly immobilized onto the scaffold surface to create a tailored, functionally active coating. This coating markedly altered the surface physicochemical properties, reducing the water contact angle from approximately 81° to 48°, and enhanced interfacial biomineralization and the osteoblastic response of MC3T3-E1 cells. Moreover, the designed substrate-coating architecture integrated bulk photothermal responsiveness with surface-mediated nanoparticle activity, enabling a synergistic therapeutic mode at the biointerface. Under near-infrared (NIR) irradiation, the photothermal heat generated by the MoS2-incorporated scaffold triggered shape-memory recovery for adaptive defect fitting while simultaneously amplifying the antibacterial and antitumor efficacy of the PD/CeO2 coating. As a result, the multifunctional scaffold achieved antibacterial rates of 92% against E. coli and 94% against S. aureus, together with a 92% ablation rate of human osteosarcoma (HOS) cells. Overall, this work demonstrates a potential functional-coating strategy for engineering a multifunctional biointerface on 3D-printed bone scaffolds, integrating surface bioactivity, NIR-triggered shape-memory behavior, and synergistic photothermal/nanoparticle therapy. These findings provide a promising design for functional coatings and surface-engineered biomaterials in the treatment of complex bone defects.
- 15 March 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105278
Harnessing synergy: Innovative combinations to overcome PARP inhibitor resistance in cancer treatment
- 15 March 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 222, 105278
Harnessing synergy: Innovative combinations to overcome PARP inhibitor resistance in cancer treatment
- Open Access
- 26 December 2025
- Published by Springer Nature in Medical Oncology
- Vol. 43 (2) , 91
ECSCR functions as a potential tumor suppressor in breast cancer cells
Breast cancer is the most commonly diagnosed malignancy among women worldwide. Triple-negative breast cancer (TNBC), a particularly aggressive subtype, is unresponsive to endocrine and targeted therapies. It is characterized by high rates of invasion and recurrence, a poor prognosis, and limited treatment options. Resveratrol, a natural polyphenolic compound, possesses well-documented anticancer properties. Given the differential sensitivity of the MDA-MB-231 (TNBC) and MCF-7 (luminal) cell lines to resveratrol, we treated these cells with resveratrol and performed RNA sequencing followed by RT-qPCR validation. Our analysis revealed significantly elevated expression of ECSCR (Endothelial Cell Surface Expressed Chemotaxis and Apoptosis Regulator) in resveratrol-treated MDA-MB-231 cells compared to controls, whereas no significant change was observed in MCF-7 cells. Although the role of ECSCR in breast cancer remains poorly characterized, we investigated its functional significance by establishing lentiviral-mediated ECSCR overexpression in breast cancer cells. In vitro, ECSCR overexpression suppressed cellular proliferation and migration while promoting apoptosis. Consistently, in vivo experiments demonstrated a reduced tumorigenic capacity of ECSCR-overexpressing cells. Collectively, our findings indicate that ECSCR exerts tumor-suppressive effects by inhibiting proliferation and migration, inducing apoptosis, and suppressing tumorigenesis. Notably, the growth-inhibitory effects of resveratrol on TNBC may be mediated through the upregulation of ECSCR. These results identify ECSCR as a promising therapeutic target for breast cancer intervention strategies.
- 26 December 2025
- Published by Springer Nature in Medical Oncology
- Vol. 43 (2) , 91
Open AccessECSCR functions as a potential tumor suppressor in breast cancer cells
Breast cancer is the most commonly diagnosed malignancy among women worldwide. Triple-negative breast cancer (TNBC), a particularly aggressive subtype, is unresponsive to endocrine and targeted therapies. It is characterized by high rates of invasion and recurrence, a poor prognosis, and limited treatment options. Resveratrol, a natural polyphenolic compound, possesses well-documented anticancer properties. Given the differential sensitivity of the MDA-MB-231 (TNBC) and MCF-7 (luminal) cell lines to resveratrol, we treated these cells with resveratrol and performed RNA sequencing followed by RT-qPCR validation. Our analysis revealed significantly elevated expression of ECSCR (Endothelial Cell Surface Expressed Chemotaxis and Apoptosis Regulator) in resveratrol-treated MDA-MB-231 cells compared to controls, whereas no significant change was observed in MCF-7 cells. Although the role of ECSCR in breast cancer remains poorly characterized, we investigated its functional significance by establishing lentiviral-mediated ECSCR overexpression in breast cancer cells. In vitro, ECSCR overexpression suppressed cellular proliferation and migration while promoting apoptosis. Consistently, in vivo experiments demonstrated a reduced tumorigenic capacity of ECSCR-overexpressing cells. Collectively, our findings indicate that ECSCR exerts tumor-suppressive effects by inhibiting proliferation and migration, inducing apoptosis, and suppressing tumorigenesis. Notably, the growth-inhibitory effects of resveratrol on TNBC may be mediated through the upregulation of ECSCR. These results identify ECSCR as a promising therapeutic target for breast cancer intervention strategies.
- 8 May 2025
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 8 (20) , 10471-10485
Dual Nano-Reinforced 3D-Printed Polylactic Acid Scaffolds for Antibacterial and Osteogenic Applications
- 8 May 2025
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 8 (20) , 10471-10485
Dual Nano-Reinforced 3D-Printed Polylactic Acid Scaffolds for Antibacterial and Osteogenic Applications
- Open Access
- 6 May 2025
- Published by Springer Nature in Cell Discovery
- Vol. 11 (1) , 1-18
A basigin antibody modulates MCTs to impact tumor metabolism and immunity
Lactate metabolism and signaling intricately intertwine in the context of cancer and immunity. Basigin, working alongside monocarboxylate transporters MCT1 and MCT4, orchestrates the movement of lactate across cell membranes. Despite their potential in treating formidable tumors, the mechanisms by which basigin antibodies affect basigin and MCTs remain unclear. Our research demonstrated that basigin positively modulates MCT activity. We subsequently developed a basigin antibody that converts basigin into a negative modulator, thereby suppressing lactate transport and enhancing anti-tumor immunity. Additionally, the antibody alters metabolic profiles in NSCLC-PDOs and T cells. Cryo-EM structural analysis and molecular dynamics simulations reveal that the extracellular Ig2 domain and transmembrane domain of basigin regulate MCT1 activity through an allosteric mechanism. The antibody decreases MCT1 transition rate by reducing the flexibility of basigin’s Ig2 domain and diminishing interactions between basigin’s transmembrane domain and MCT1. These findings underscore the promise of basigin antibodies in combating tumors by modulating metabolism and immunity, and the value of a common therapeutic subunit shared by multiple transporter targets.
- 6 May 2025
- Published by Springer Nature in Cell Discovery
- Vol. 11 (1) , 1-18
Open AccessA basigin antibody modulates MCTs to impact tumor metabolism and immunity
Lactate metabolism and signaling intricately intertwine in the context of cancer and immunity. Basigin, working alongside monocarboxylate transporters MCT1 and MCT4, orchestrates the movement of lactate across cell membranes. Despite their potential in treating formidable tumors, the mechanisms by which basigin antibodies affect basigin and MCTs remain unclear. Our research demonstrated that basigin positively modulates MCT activity. We subsequently developed a basigin antibody that converts basigin into a negative modulator, thereby suppressing lactate transport and enhancing anti-tumor immunity. Additionally, the antibody alters metabolic profiles in NSCLC-PDOs and T cells. Cryo-EM structural analysis and molecular dynamics simulations reveal that the extracellular Ig2 domain and transmembrane domain of basigin regulate MCT1 activity through an allosteric mechanism. The antibody decreases MCT1 transition rate by reducing the flexibility of basigin’s Ig2 domain and diminishing interactions between basigin’s transmembrane domain and MCT1. These findings underscore the promise of basigin antibodies in combating tumors by modulating metabolism and immunity, and the value of a common therapeutic subunit shared by multiple transporter targets.
- Open Access
- 5 April 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 295, 118139
Arsenic exposure provoked prostatic PANoptosis by inducing mitochondrial dysfunction in mice and WPMY-1 cells
- 5 April 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 295, 118139
Open AccessArsenic exposure provoked prostatic PANoptosis by inducing mitochondrial dysfunction in mice and WPMY-1 cells
- 26 March 2025
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 7 (7) , 4572-4583
3D-Printed Thermally Activated Shape Memory PLA/TBC Composite Scaffold with Body-Compatible Temperature for Minimally Invasive Bone Repair
- 26 March 2025
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 7 (7) , 4572-4583
3D-Printed Thermally Activated Shape Memory PLA/TBC Composite Scaffold with Body-Compatible Temperature for Minimally Invasive Bone Repair
- Open Access
- 26 June 2024
- Published by Springer Nature in Clinical Proteomics
- Vol. 21 (1) , 1-14
Proteomic profiling of prostate cancer reveals molecular signatures under antiandrogen treatment
Background: Tumorigenesis and progression of prostate cancer (PCa) are indispensably dependent on androgen receptor (AR). Antiandrogen treatment is the principal preference for patients with advanced PCa. However, the molecular characteristics of PCa with antiandrogen intervention have not yet been fully uncovered. Methods: We first performed proteome analysis with 32 PCa tumor samples and 10 adjacent tissues using data-independent acquisition (DIA)- parallel accumulation serial fragmentation (PASEF) proteomics. Then label-free quantification (LFQ) mass spectrometry was employed to analyze protein profiles in LNCaP and PC3 cells. Results: M-type creatine kinase CKM and cartilage oligomeric matrix protein COMP were demonstrated to have the potential to be diagnostic biomarkers for PCa at both mRNA and protein levels. Several E3 ubiquitin ligases and deubiquitinating enzymes (DUBs) were significantly altered in PCa and PCa cells under enzalutamide treatment, and these proteins might reprogram proteostasis at protein levels in PCa. Finally, we discovered 127 significantly varied proteins in PCa samples with antiandrogen therapy and further uncovered 4 proteins in LNCaP cells upon enzalutamide treatment. Conclusions: Our research reveals new potential diagnostic biomarkers for prostate cancer and might help resensitize resistance to antiandrogen therapy.
- 26 June 2024
- Published by Springer Nature in Clinical Proteomics
- Vol. 21 (1) , 1-14
Open AccessProteomic profiling of prostate cancer reveals molecular signatures under antiandrogen treatment
Background: Tumorigenesis and progression of prostate cancer (PCa) are indispensably dependent on androgen receptor (AR). Antiandrogen treatment is the principal preference for patients with advanced PCa. However, the molecular characteristics of PCa with antiandrogen intervention have not yet been fully uncovered. Methods: We first performed proteome analysis with 32 PCa tumor samples and 10 adjacent tissues using data-independent acquisition (DIA)- parallel accumulation serial fragmentation (PASEF) proteomics. Then label-free quantification (LFQ) mass spectrometry was employed to analyze protein profiles in LNCaP and PC3 cells. Results: M-type creatine kinase CKM and cartilage oligomeric matrix protein COMP were demonstrated to have the potential to be diagnostic biomarkers for PCa at both mRNA and protein levels. Several E3 ubiquitin ligases and deubiquitinating enzymes (DUBs) were significantly altered in PCa and PCa cells under enzalutamide treatment, and these proteins might reprogram proteostasis at protein levels in PCa. Finally, we discovered 127 significantly varied proteins in PCa samples with antiandrogen therapy and further uncovered 4 proteins in LNCaP cells upon enzalutamide treatment. Conclusions: Our research reveals new potential diagnostic biomarkers for prostate cancer and might help resensitize resistance to antiandrogen therapy.